This page provides you with brief summaries of our pivotal clinical trial data and comprehensive information on our approved indications and reimbursement policies for our innovative cancer treatments. Our portfolio of oncology medicines includes innovative therapies that target key biological pathways and expand our understanding of immune cell therapy. Explore our oncology medicines and learn how we are contributing to the advancement of cancer treatment.
November 2023 – Q4W 480 mg dosing with Nivolumab is approved in all melanoma indications.
Q4W dosing is approved for all Nivolumab monotherapy in melanoma as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment
July 2023 – Nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumor size ≥ 4cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumor expression ≥1% in adults